For the year ending 2025-12-31, TLSI has $35,331K in assets. $69,192K in debts. $20,439K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 20,439 | |||
| Accounts receivable, net | 6,558 | |||
| Inventory, net | 3,077 | |||
| Prepaid expenses | 2,170 | |||
| Total current assets | 32,244 | |||
| Property and equipment, net | 1,808 | |||
| Right-of-use assets | 861 | |||
| Other assets | 418 | |||
| Total assets | 35,331 | |||
| Trade payables | 3,002 | |||
| Accrued liabilities | 8,096 | |||
| Short-term lease liabilities | 167 | |||
| Other current liabilities | 234 | |||
| Total current liabilities | 11,499 | |||
| Long-term debt | 33,046 | |||
| Revenue base redemption liability | 383 | |||
| Long-term lease liabilities | 1,228 | |||
| Contingent earnout liability | 10,144 | |||
| Warrant and sepa liabilities | 12,892 | |||
| Total liabilities | 69,192 | |||
| Common stock, 0.0001 par value, 400,000,000 shares authorized at december31, 2025 and 2024, respectively 49,997,836 shares and 31,279,264 shares issued and outstanding at december31, 2025 and 2024, respectively | 4 | |||
| Additional paid-in capital | 296,718 | |||
| Accumulated deficit | -330,583 | |||
| Total stockholders deficit | -33,861 | |||
| Total liabilities and stockholders deficit | 35,331 | |||
TriSalus Life Sciences, Inc. (TLSI)
TriSalus Life Sciences, Inc. (TLSI)